HAEMONETICS CORP/MASS (HAE) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:HAE - US4050241003 - Common Stock
83.94 USD
+0.13 (+0.16%)
83.94 USD
0 (0%)
Overall HAE gets a fundamental rating of 5 out of 10. We evaluated HAE against 187 industry peers in the Health Care Equipment & Supplies industry. While HAE has a great profitability rating, there are some minor concerns on its financial health. HAE is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
HAE had positive earnings in the past year.
HAE had a positive operating cash flow in the past year.
HAE had positive earnings in each of the past 5 years.
Each year in the past 5 years HAE had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 6.89%, HAE belongs to the best of the industry, outperforming 87.30% of the companies in the same industry.
The Return On Equity of HAE (19.81%) is better than 94.18% of its industry peers.
HAE's Return On Invested Capital of 10.48% is amongst the best of the industry. HAE outperforms 89.95% of its industry peers.
HAE had an Average Return On Invested Capital over the past 3 years of 8.96%. This is in line with the industry average of 8.81%.
The last Return On Invested Capital (10.48%) for HAE is above the 3 year average (8.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.89% | ||
| ROE | 19.81% | ||
| ROIC | 10.48% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
1.3 Margins
HAE has a better Profit Margin (12.67%) than 89.42% of its industry peers.
In the last couple of years the Profit Margin of HAE has grown nicely.
The Operating Margin of HAE (19.11%) is better than 92.06% of its industry peers.
HAE's Operating Margin has been stable in the last couple of years.
HAE has a Gross Margin (58.46%) which is in line with its industry peers.
HAE's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.11% | ||
| PM (TTM) | 12.67% | ||
| GM | 58.46% |
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HAE is creating some value.
The number of shares outstanding for HAE has been reduced compared to 1 year ago.
HAE has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, HAE has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.73 indicates that HAE is not a great score, but indicates only limited risk for bankruptcy at the moment.
HAE has a Altman-Z score of 2.73. This is in the better half of the industry: HAE outperforms 67.72% of its industry peers.
The Debt to FCF ratio of HAE is 5.76, which is a neutral value as it means it would take HAE, 5.76 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.76, HAE is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
A Debt/Equity ratio of 1.08 is on the high side and indicates that HAE has dependencies on debt financing.
With a Debt to Equity ratio value of 1.08, HAE is not doing good in the industry: 75.66% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 5.76 | ||
| Altman-Z | 2.73 |
ROIC/WACC1.45
WACC7.24%
2.3 Liquidity
HAE has a Current Ratio of 1.64. This is a normal value and indicates that HAE is financially healthy and should not expect problems in meeting its short term obligations.
HAE's Current ratio of 1.64 is on the low side compared to the rest of the industry. HAE is outperformed by 71.43% of its industry peers.
HAE has a Quick Ratio of 1.03. This is a normal value and indicates that HAE is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of HAE (1.03) is worse than 75.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.64 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 17.65% over the past year.
The Earnings Per Share has been growing slightly by 6.66% on average over the past years.
HAE shows a decrease in Revenue. In the last year, the revenue decreased by -2.45%.
The Revenue has been growing slightly by 6.60% on average over the past years.
EPS 1Y (TTM)17.65%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%13.39%
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-5.27%
3.2 Future
HAE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.81% yearly.
The Revenue is expected to grow by 3.31% on average over the next years.
EPS Next Y8.59%
EPS Next 2Y10.16%
EPS Next 3Y10.81%
EPS Next 5YN/A
Revenue Next Year-3.06%
Revenue Next 2Y1.37%
Revenue Next 3Y3.31%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 17.49, which indicates a rather expensive current valuation of HAE.
Based on the Price/Earnings ratio, HAE is valued cheaply inside the industry as 85.19% of the companies are valued more expensively.
HAE is valuated rather cheaply when we compare the Price/Earnings ratio to 26.49, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 15.14, which indicates a correct valuation of HAE.
86.77% of the companies in the same industry are more expensive than HAE, based on the Price/Forward Earnings ratio.
HAE is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.69, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.49 | ||
| Fwd PE | 15.14 |
4.2 Price Multiples
85.19% of the companies in the same industry are more expensive than HAE, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, HAE is valued cheaply inside the industry as 90.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.48 | ||
| EV/EBITDA | 13.2 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HAE does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of HAE may justify a higher PE ratio.
PEG (NY)2.04
PEG (5Y)2.62
EPS Next 2Y10.16%
EPS Next 3Y10.81%
5. Dividend
5.1 Amount
No dividends for HAE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
83.94
+0.13 (+0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners113.48%
Inst Owner Change-4.51%
Ins Owners1.17%
Ins Owner Change1.67%
Market Cap3.93B
Revenue(TTM)1.33B
Net Income(TTM)168.19M
Analysts82.67
Price Target86.24 (2.74%)
Short Float %6.47%
Short Ratio3.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.23%
Min EPS beat(2)7.2%
Max EPS beat(2)13.26%
EPS beat(4)4
Avg EPS beat(4)5.44%
Min EPS beat(4)0.62%
Max EPS beat(4)13.26%
EPS beat(8)7
Avg EPS beat(8)4.36%
EPS beat(12)11
Avg EPS beat(12)8.38%
EPS beat(16)15
Avg EPS beat(16)9.71%
Revenue beat(2)2
Avg Revenue beat(2)4.31%
Min Revenue beat(2)4.07%
Max Revenue beat(2)4.55%
Revenue beat(4)2
Avg Revenue beat(4)1.44%
Min Revenue beat(4)-2.22%
Max Revenue beat(4)4.55%
Revenue beat(8)4
Avg Revenue beat(8)1.51%
Revenue beat(12)8
Avg Revenue beat(12)1.89%
Revenue beat(16)11
Avg Revenue beat(16)2.17%
PT rev (1m)8.81%
PT rev (3m)5.29%
EPS NQ rev (1m)-0.02%
EPS NQ rev (3m)-1.36%
EPS NY rev (1m)1.81%
EPS NY rev (3m)1.84%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.9%
Revenue NY rev (1m)1.84%
Revenue NY rev (3m)1.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.49 | ||
| Fwd PE | 15.14 | ||
| P/S | 2.96 | ||
| P/FCF | 18.48 | ||
| P/OCF | 13.59 | ||
| P/B | 4.63 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.2 |
EPS(TTM)4.8
EY5.72%
EPS(NY)5.55
Fwd EY6.61%
FCF(TTM)4.54
FCFY5.41%
OCF(TTM)6.17
OCFY7.36%
SpS28.37
BVpS18.14
TBVpS-3.96
PEG (NY)2.04
PEG (5Y)2.62
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.89% | ||
| ROE | 19.81% | ||
| ROCE | 13.4% | ||
| ROIC | 10.48% | ||
| ROICexc | 12.43% | ||
| ROICexgc | 35.27% | ||
| OM | 19.11% | ||
| PM (TTM) | 12.67% | ||
| GM | 58.46% | ||
| FCFM | 16.01% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
ROICexc(3y)10.46%
ROICexc(5y)8.47%
ROICexgc(3y)26.78%
ROICexgc(5y)22.33%
ROCE(3y)11.45%
ROCE(5y)9.23%
ROICexgc growth 3Y22.36%
ROICexgc growth 5Y7.33%
ROICexc growth 3Y21.7%
ROICexc growth 5Y-5.09%
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
F-Score8
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 5.76 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 66.93% | ||
| Cap/Sales | 5.76% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 78.54% | ||
| Profit Quality | 126.39% | ||
| Current Ratio | 1.64 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z | 2.73 |
F-Score8
WACC7.24%
ROIC/WACC1.45
Cap/Depr(3y)79.52%
Cap/Depr(5y)76.24%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.58%
Profit Quality(3y)103.91%
Profit Quality(5y)115.34%
High Growth Momentum
Growth
EPS 1Y (TTM)17.65%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%13.39%
EPS Next Y8.59%
EPS Next 2Y10.16%
EPS Next 3Y10.81%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-5.27%
Revenue Next Year-3.06%
Revenue Next 2Y1.37%
Revenue Next 3Y3.31%
Revenue Next 5YN/A
EBIT growth 1Y18%
EBIT growth 3Y34.59%
EBIT growth 5Y7.12%
EBIT Next Year34.68%
EBIT Next 3Y14.45%
EBIT Next 5YN/A
FCF growth 1Y6.71%
FCF growth 3Y16.98%
FCF growth 5Y2.09%
OCF growth 1Y10.19%
OCF growth 3Y1.79%
OCF growth 5Y2.81%
HAEMONETICS CORP/MASS / HAE FAQ
What is the ChartMill fundamental rating of HAEMONETICS CORP/MASS (HAE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to HAE.
What is the valuation status for HAE stock?
ChartMill assigns a valuation rating of 6 / 10 to HAEMONETICS CORP/MASS (HAE). This can be considered as Fairly Valued.
How profitable is HAEMONETICS CORP/MASS (HAE) stock?
HAEMONETICS CORP/MASS (HAE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of HAEMONETICS CORP/MASS (HAE) stock?
The Price/Earnings (PE) ratio for HAEMONETICS CORP/MASS (HAE) is 17.49 and the Price/Book (PB) ratio is 4.63.